Dynamic Individualized Risk Profiling of Patients With Relapsed/Refractory Lymphoid Malignancies and CD19-CAR T Cell Therapy (INTeRCePT 2.0)

Recruiting now

Conditions studied: Lymphoma, Lymphoid Hematological Malignancies

In brief

The INTeRCePT 2 study aims to develop a predictive assay to determine which patients with B cell lymphoma are most likely to respond to CAR T cell therapy. This assay combines five components for longitudinal profiling of each patient. The goal of the trial is that the assay can be completed (feasibility). This comprehensive assay integrates five key components including circulating tumor DNA (CAPPseq), inflammation markers from peripheral blood tests (InflaMIX), PET CT imaging parameters, immune cell profiles (flow cytometry), and performance status (ECOG). Ultimately, this tool could improve treatment selection, and guide more personalized therapy decisions for lymphoma patients receiving CAR T cells.

Key facts

Study ID

NCT07472972

Run by

University of Zurich

People needed

50

Starts

2025-06-20

Expected to finish

2030-05-31

Last updated by the study team

2026-03-16

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Written informed consent before registration and prior to any trial specific procedures
• Participants ≥ 18 years of age
• Diagnosis of relapse/refractory B-cell lymphoma according to WHO 2022 classification
• Measurable disease per response criteria specific to the disease e.g. per Lugano 2014 criteria
• Patients planned for CD19-redirected CAR T cell therapy according to clinical standard of care
• Patients who are willing to donate peripheral blood and biopsy material at indicated clinical visits

You may not qualify if…

• Any condition, which precludes initiation of CD19-redirected CAR T cell therapy (e.g. breast feeding, pregnancy, infections, etc.) as judged by the treating physician
• Any coexisting medical or psychological condition that would preclude participation in the required study procedures, as judged by the treating physician
• Unwillingness or inability to comply with the protocol

Where it is running

• Universityhospital Zurich, Department of Medical Oncology and Hematology — Zurich, Canton of Zurich, Switzerland (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.